A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin

Diabetes/Metabolism Research and Reviews

Volumn 33, Issue 3, 2017, Pages

  Raccah, Denis ^a   Chou, Engels ^b   Colagiuri, Stephen ^c   Gaàl, Zsolt ^d   Lavalle, Fernando ^e   Mkrtumyan, Ashot ^f   Nikonova, Elena ^b   Tentolouris, Nikolaos ^g   Vidal, Josep ^h   Davies, Melanie ⁱ  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b SANOFI   (France)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Josa Andras Teaching Hospital   (Hungary)

^e Medicina UANL   (Mexico)

^f A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

fasting plasma glucose; glycemic control; insulin therapy; postprandial glucose; residual hyperglycemia; type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; DIET RESTRICTION; ELECTRONIC MEDICAL RECORD; EUROPE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SOUTH AND CENTRAL AMERICA; UNITED STATES; BLOOD; DIABETES MELLITUS, TYPE 2; GLOBAL HEALTH; METABOLISM; NEEDS ASSESSMENT; PHYSIOLOGY; PROGNOSIS;

BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; GLOBAL HEALTH; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; NEEDS ASSESSMENT; PROGNOSIS;

EID: 84991355089     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2858     Document Type: Article

References (50)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853.
2. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589.
3. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104(1):1–52.
4. American Diabetes Association. Standards of care: approaches to glycemic treatment. Diabetes Care. 2015;38(suppl 1):S41–S47.
5. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149.
6. National Institute for Health and Clinical Excellence. Primary Care Quality and Outcomes Framework Indicator Advisory Committee recommendations. http://www.nice.org.uk/guidance/cg87/resources/guidance-type-2-diabetes-pdf. Accessed February 16, 2015.
7. Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement—executive summary. Endocr Pract. 2013;19(3):536–557.
8. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–885.
9. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care. 2011;34(12):2508–2514.
10. Wang JS, Tu ST, Lee IT, et al. Contribution of postprandial glucose to excess hyperglycaemia in Asian type 2 diabetic patients using continuous glucose monitoring. Diabetes Metab Res Rev. 2011;27(1):79–84.
11. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080–3086.
12. Raccah D, Bretzel RG, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough—what next? Diabetes Metab Res Rev. 2007;23(4):257–264.
13. Peter R, Dunseath G, Luzio SD, Owens DR. Estimates of the relative and absolute diurnal contributions of fasting and post-prandial plasma glucose over a range of hyperglycaemia in type 2 diabetes. Diabetes Metab. 2013;39(4):337–342.
14. 1c levels. Diabetes Res Clin Pract. 2007;77(2):280–285.
15. Arnolds S, Dellweg S, Clair J, et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care. 2010;33(7):1509–1515.
16. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497–2503.
17. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103–112.
18. American Diabetes Association. Clinical practice recommendations 1995. Diabetes Care. 1995;18(suppl 1):S1–S96.
19. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379.
20. American Diabetes Association Standards of Medical Care in Diabetes—2009. Diabetes Care. 2009;32(Suppl 1):S13–S61.
21. Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 2006;37(4):495–501.
22. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138(12):952–959.
23. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28(2):254–259.
24. Pan CY, Sinnassamy P, Chung KD, Kim KW. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Res Clin Pract. 2007;76(1):111–118.
25. Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33(6):1176–1178.
26. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49(3):442–451.
27. Kawamori R. Efficacy and safety of insulin glargine in concurrent use with oral hypoglycaemic agents for the treatment of type 2 diabetes patients. Rinsho Iyaku. 2003;19(1):445–464.
28. Ohtani T, Ito T. Safety and effectiveness of BOT (basal supported oral therapy) using insulin glargine in Japanese patients with type 2 diabetes—results from postmarketing surveillance of insulin glargine (ALOHA study) Shinyaku to Rinsho. J New Rem Clin. 2011;6:458–475.
29. Freemantle N, Evans M, Christensen T, Wolden ML, Bjorner JB. A comparison of health-related quality of life (health utility) between insulin degludec and insulin glargine: a meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(6):564–571.
30. Tsai ST, Pathan F, Ji L, et al. First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes. 2011;3(3):208–216.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
32. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998;15(4):290–296.
33. Ostgren CJ, Lindblad U, Ranstam J, Melander A, Rastam L. Glycaemic control, disease duration and beta-cell function in patients with type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabet Med. 2002;19(2):125–129.
34. Pound N, Sturrock ND, Jeffcoate WJ. Age related changes in glycated haemoglobin in patients with insulin-dependent diabetes mellitus. Diabet Med. 1996;13(6):510–513.
35. Valle T, Koivisto VA, Reunanen A, Kangas T, Rissanen A. Glycemic control in patients with diabetes in Finland. Diabetes Care. 1999;22(4):575–579.
36. McGill JB, Vlajnic A, Knutsen PG, Recklein C, Rimler M, Fisher SJ. Effect of gender on treatment outcomes in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2013;102(3):167–174.
37. Ewenighi CO, Uchechukwu D, Adejumo BI, et al. Responses to glycemic control therapy according to age, gender, level of adiposity, and duration of diabetes in type 2 diabetic patients. Indian J Med Sci. 2013;67(3-4):61–69.
38. Lankisch MR, Ferlinz KC, Leahy JL, Scherbaum WA. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes Obes Metab. 2008;10(12):1178–1185.
39. Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract. 2011;17(3):395–403.
40. Owens DR, Luzio SD, Sert-Langeron C, Riddle MC. Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study. Diabetes Obes Metab. 2011;13(11):1020–1027.
41. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39–47.
42. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187–1194.
43. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742.
44. Ahren B, Gautier JF, Berria R, Stager W, Aronson R, Bailey CJ. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(9):861–868.
45. Edwards CM, Stanley SA, Davis R, et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab. 2001;281(1):E155–E161.
46. Lorenz M, Pfeiffer C, Steinstrasser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes—relationship to postprandial glycemia. Regul Pept. 2013;185:C1–C8.
47. Meier JJ, Yabe D, Wang E, Lin J, Rosenstock J, Ahrén B. Efficacy of lixisenatide in patients with different levels of beta cell function as assessed by C-peptide/glucose ratio. Diabetologia. 2013;56(suppl 1):S1–S566. (Abstract 896)
48. Meier JJ, Rosenstock J, Hincelin-Mery A, et al. Effect of lixisenatide vs liraglutide on glycemic control, gastric emptying, and safety parameters in optimized insulin glargine T2DM ± metformin. Presented at the 74th Scientific Sessions of the American Diabetes Association, San Francisco, CA, USA, 13–17 June 2014, 1017-P.
49. 1c of 7% (53 mmol/mol) in persons with type 2 diabetes. Diabetes Res Clin Pract. 2014;104(3):370–375.
50. Monnier L, Colette C, Dejager S, Owens D. “Mild dysglycemia” in type 2 diabetes: to be neglected or not? J Diabetes Complications. 2015;29(3):451–458.